TY - JOUR
T1 - The ketogenic diet all grown up—Ketogenic diet therapies for adults
AU - Husari, Khalil S.
AU - Cervenka, Mackenzie C.
N1 - Funding Information:
MCC: Dr. Cervenka receives grants from Nutricia, Vitaflo, BrightFocus Foundation, and Army Research Laboratory. Honoraria from American Epilepsy Society, The Neurology Center, Epigenix, LivaNova, and Nutricia. Royalties from Demos. Consulting for Nutricia, Sage Therapeutics.
Funding Information:
MCC: Dr. Cervenka receives grants from Nutricia,Vitaflo,BrightFocus Foundation, andArmy Research Laboratory. Honoraria from American Epilepsy Society, The Neurology Center, Epigenix, LivaNova, and Nutricia. Royalties from Demos. Consulting for Nutricia, Sage Therapeutics.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/5
Y1 - 2020/5
N2 - The use of ketogenic diet therapies (KDT) in adults has expanded in the last two decades and has been accompanied by a surge of new retrospective as well as prospective studies evaluating its efficacy in adults with epilepsy. In this review article, we will highlight the recent clinical trials and advances in the use of the ketogenic diet therapy (KDT) in adult patients with epilepsy. We will analyze the responder rate in regard to the epilepsy syndrome (focal vs generalized) to identify adults who are optimal to consider for KDT. In addition to its role in treating patients with chronic epilepsy, we will explore the emerging use of the KDT in the critical care setting in adults with refractory and super-refractory status epilepticus as well as other neurologic disorders. Finally, we will discuss special considerations for the use of KDT in adults with epilepsy including its potential long-term effects on bone and cardiovascular health, and its use in pregnancy.
AB - The use of ketogenic diet therapies (KDT) in adults has expanded in the last two decades and has been accompanied by a surge of new retrospective as well as prospective studies evaluating its efficacy in adults with epilepsy. In this review article, we will highlight the recent clinical trials and advances in the use of the ketogenic diet therapy (KDT) in adult patients with epilepsy. We will analyze the responder rate in regard to the epilepsy syndrome (focal vs generalized) to identify adults who are optimal to consider for KDT. In addition to its role in treating patients with chronic epilepsy, we will explore the emerging use of the KDT in the critical care setting in adults with refractory and super-refractory status epilepticus as well as other neurologic disorders. Finally, we will discuss special considerations for the use of KDT in adults with epilepsy including its potential long-term effects on bone and cardiovascular health, and its use in pregnancy.
KW - Drug-resistant epilepsy (DRE)
KW - Modified Atkins diet (MAD)
KW - Refractory status epilepctius (RSE)
UR - http://www.scopus.com/inward/record.url?scp=85081659996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081659996&partnerID=8YFLogxK
U2 - 10.1016/j.eplepsyres.2020.106319
DO - 10.1016/j.eplepsyres.2020.106319
M3 - Review article
C2 - 32199222
AN - SCOPUS:85081659996
SN - 0920-1211
VL - 162
JO - Epilepsy Research
JF - Epilepsy Research
M1 - 106319
ER -